|
|
|
Insider
Information: |
Boyd Steven |
Relationship: |
10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
18 |
|
Direct
Shares |
47,075,098 |
|
Indirect Shares
|
40,287,245 |
|
|
Direct
Value |
$128,455,406 |
|
|
Indirect Value
|
$40,265,984 |
|
|
Total
Shares |
87,362,343 |
|
|
Total
Value |
$168,721,391 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
99
|
96
|
Stock
price went up :
|
54
|
46
|
Stock
price went down : |
45
|
50
|
|
|
|
Gain/Loss Ratio : |
1.2
|
1.2
|
Percentage
Gain/Loss : |
-16.7%
|
8,928.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Avalo Therapeutics, Inc |
AVTX |
10% Owner |
2023-06-27 |
34,370 |
2023-06-27 |
731,458 |
Premium* |
|
Dynatronics Corp |
DYNT |
10% Owner |
2017-03-21 |
500,000 |
2017-03-21 |
1,000,000 |
Premium* |
|
Kiora Pharmaceuticals |
KPRX |
10% Owner |
2021-01-06 |
3,346,601 |
2021-08-02 |
785,000 |
Premium* |
|
Fresh Tracks Therapeutics Ord Shs |
FRTX |
10% Owner |
2019-01-10 |
2,170,000 |
2019-01-10 |
2,170,000 |
Premium* |
|
Alimera Sciences Inc |
ALIM |
10% Owner |
2018-02-06 |
6,936,000 |
2018-02-06 |
6,936,000 |
Premium* |
|
Cassava Sciences Inc |
SAVA |
10% Owner |
2018-10-03 |
1,651,340 |
2018-10-03 |
0 |
Premium* |
|
Del Friscos Restaurant Group, Llc |
DFRG |
10% Owner |
2019-09-25 |
0 |
2019-09-25 |
0 |
Premium* |
|
Valeritas Holdings Inc |
VLRX |
10% Owner |
2019-12-20 |
0 |
2019-12-20 |
0 |
Premium* |
|
Bio-Path Holdings, Inc. |
BPTH |
10% Owner |
2019-01-18 |
129,298 |
2019-01-18 |
129,298 |
Premium* |
|
AYTU BIOSCIENCE, INC |
AYTU |
Director |
2021-03-29 |
1,342,378 |
2021-03-29 |
1,342,378 |
Premium* |
|
Achieve Life Sciences Inc |
ACHV |
10% Owner |
2019-06-11 |
843,776 |
2019-06-11 |
843,776 |
Premium* |
|
AMAG Pharmaceuticals Inc |
AMAG |
10% Owner |
2020-03-16 |
4,120,000 |
2020-03-16 |
348,000 |
Premium* |
|
Onconova Therapeutics, Inc. |
ONTX |
10% Owner |
2019-09-23 |
816,702 |
2019-09-23 |
816,702 |
Premium* |
|
Vaxart Inc |
VXRT |
Director |
2020-06-29 |
145,523 |
2020-06-29 |
145,523 |
Premium* |
|
Tetraphase Pharmaceuticals Inc |
TTPH |
Director, 10% Owner |
2020-07-28 |
0 |
2020-07-28 |
0 |
Premium* |
|
Tenax Therapeutics Inc |
TENX |
Director, 10% Owner |
2020-09-08 |
2,019,995 |
2020-09-08 |
2,019,995 |
Premium* |
|
Cyclo Therapeutics, Inc |
CYTH |
10% Owner |
2020-09-30 |
15,795,769 |
2020-09-30 |
15,795,769 |
Premium* |
|
ReShape Lifesciences Inc |
RSLS |
10% Owner |
2021-06-28 |
7,223,346 |
2021-06-28 |
7,223,346 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
790 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 17 of 32
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VXRT |
Vaxart Inc |
Director |
|
2020-05-05 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
15,950,000 |
0 |
% |
|
VXRT |
Vaxart Inc |
Director |
|
2020-05-05 |
4 |
S |
$2.66 |
$1,842,132 |
D/D |
(692,531) |
15,950,000 |
0 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-09-20 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
15,964,505 |
2.17 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-09-20 |
4 |
B |
$0.76 |
$11,610 |
D/D |
15,250 |
15,964,505 |
3.92 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-09-21 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
15,966,865 |
2.17 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-09-21 |
4 |
B |
$0.79 |
$1,853 |
D/D |
2,360 |
15,966,865 |
3.84 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-09-22 |
4 |
B |
$0.78 |
$9,641 |
D/D |
12,300 |
15,979,165 |
3.84 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-09-22 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
15,979,165 |
2.17 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2017-09-26 |
4 |
B |
$0.80 |
$10,774 |
D/D |
13,552 |
15,992,717 |
2.37 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2017-09-26 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
15,992,717 |
1.42 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2017-09-27 |
4 |
B |
$0.81 |
$81 |
D/D |
100 |
15,992,817 |
2.37 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2017-09-27 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
15,992,817 |
1.42 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2017-09-28 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
15,993,117 |
1.42 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2017-09-28 |
4 |
B |
$0.84 |
$251 |
D/D |
300 |
15,993,117 |
2.37 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-09-29 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,000,000 |
2.17 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-09-29 |
4 |
B |
$0.87 |
$5,986 |
D/D |
6,883 |
16,000,000 |
3.84 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-10-16 |
4 |
B |
$1.08 |
$5,174 |
D/D |
4,800 |
16,004,800 |
3.84 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-10-16 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,004,800 |
2.17 |
- |
|
CYTH |
Cyclo Therapeutics, Inc |
10% Owner |
|
2020-09-16 |
4 |
S |
$0.16 |
$20,000 |
D/D |
(125,000) |
16,016,492 |
0 |
% |
|
CYTH |
Cyclo Therapeutics, Inc |
10% Owner |
|
2020-09-16 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
16,016,492 |
0 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-11-22 |
4 |
B |
$1.20 |
$42,210 |
D/D |
35,200 |
16,040,000 |
3.92 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-11-22 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,040,000 |
2.17 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-11-24 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,050,000 |
2.17 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2017-11-24 |
4 |
B |
$1.20 |
$11,980 |
D/D |
10,000 |
16,050,000 |
3.92 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2018-04-16 |
4 |
B |
$3.36 |
$137,885 |
D/D |
41,096 |
16,091,096 |
3.92 |
- |
|
790 Records found
|
|
Page 17 of 32 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|